منابع مشابه
Preeclampsia – Will Orphan Drug Status Facilitate Innovative Biological Therapies?
It is generally accepted that the development of novel therapies to treat pregnancy-related disorders, such as preeclampsia, is hampered by the paucity of research funding. Hence, it is with great interest to become aware of at least three novel therapeutic approaches for the treatment of this disorder: exploiting either the anticoagulant activity of antithrombin, the free radical scavenging ac...
متن کاملMethadone: An Orphan Drug?
73 Dear Editor: A pharmaceutical product is called “orphan drug” when, although promising or clearly valid from a scientific and therapeutic point of view, it is not profit-bearing and, therefore, not interesting for the pharmaceutical industry. The consequences are the lack of extensive research on its effects, and mainly, the lack of appropriate information to physicians, nurses, and administ...
متن کاملReconsidering GHB: orphan drug or new model antidepressant?
For six decades, the principal mode of action of antidepressant drugs is the inhibition of monoamine re-uptake from the synaptic cleft. Tricyclic antidepressants, selective serotonin re-uptake inhibitors (SSRIs) and the new generation of dual antidepressants all exert their antidepressant effects by this mechanism. In the early days of the monoaminergic era, other efforts have been made to amel...
متن کاملEngineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
In this study, we have engineered a new mycobacterial vaccine design by using an antibiotic-free plasmid selection system. We assembled a novel Escherichia coli (E. coli)-mycobacterial shuttle plasmid p2auxo.HIVA, expressing the HIV-1 clade A immunogen HIVA. This shuttle vector employs an antibiotic resistance-free mechanism for plasmid selection and maintenance based on glycine complementation...
متن کاملOrphan/rare drug discovery through drug repositioning
There are many, often life-threatening, rare/orphan diseases for which there are few or no therapeutic options. They individually affect few people, but collectively impose very high social and economic burdens. New approaches are bringing big pharma resources to solving the problem through drug repositioning of approved drugs. Advances are being spurred by public and private partnerships, gove...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2005
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.331.7530.1476